Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor

Pathology International

Volumn 62, Issue 7, 2012, Pages 471-476

  Nagata, Chigusa ^a   Kobayashi, Hiromi ^a   Sakata, Akiko ^a   Satomi, Kaishi ^a   Minami, Yuko ^a   Morishita, Yukio ^a   Ohara, Rena ^b   Yoshikawa, Hiroyuki ^b   Arai, Yuko ^c   Nishida, Masato ^c   Noguchi, Masayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c National Hospital Organization Kasumigaura Medical Center   (Japan)

Author keywords

Malignancy; OCIAD2; Ovarian mucinous tumor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; OCANCER IMMUNOREACTIVE ANTIGEN DOMAIN CONTAINING 1; OCANCER IMMUNOREACTIVE ANTIGEN DOMAIN CONTAINING 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARIAN MUCINOUS TUMOR; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL;

ADENOCARCINOMA, MUCINOUS; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862889047     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2012.02825.x     Document Type: Article

References (19)

1. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathol 2001; 38: 87-95.
2. Shih IEM, Kurman RJ. Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. Am J Pathol 2004; 164: 1511-8.
3. Kurman RJ, Shih IEM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-31.
4. Auner V, Kriegshäuser G, Tong D etal. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009; 9: 111-8.
5. Kurman RJ, Visvanathan K, Roden R etal. Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198: 351-6.
6. Kurman RJ, Shil IEM. Pathogenesis of Ovarian Cancer. Lessons from Morphology and Molecular Biology and their Clinical Implications. Int J Gynecol Pathol 2008; 27: 151-60.
7. Ishiyama T, Kano J, Anami Y etal. OCIA domain containing 2 is highly expressed in adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component and is associated with better prognosis. Cancer Sci 2007; 98: 50-7.
8. Luo LY, Soosaipillai A, Diamandis EP. Molecular cloning of a novel human gene on chromosome 4p11 by immunoscreening of an ovarian carcinoma cDNA library. Biochem Biophys Res Commun 2001; 280: 401-6.
9. Sengupta S, Michener CM, Escober P etal. Ovarian cancer immuno-reactive antigen domain containimg 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol Oncol 2008; 109: 226-33.
10. Wang C, Michener CM, Belinson JL etal. Role of the 18:1 lysophosphatidic acid-ovarian cancer immunoreactive antigen domain containing 1 (OCIAD1)-integrin axis in generating late-stage ovarian cancer. Mol Cancer Ther 2010; 9: 1709-18.
11. Tavassoli FA, Devilee P, eds. World Health Organization: Tumours of the Breast and Female Genital Organs (WHO/IARC Classification of Tumours). Lyon: IARC Press, 2003.
12. Cho KR, Shih IEM. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
13. Kaku T, Ogawa S, Kawano Y etal. Histological classification of ovarian cancer. Med Electron Microsc 2003; 36: 9-17.
14. Koskas M, Uzan C, Gouy S etal. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 2011; 18: 40-8.
15. McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumors. Curr Opin Oncol 2010; 22: 462-72.
16. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005; 18: 33-50.
17. Chen S, Leitao MM, Tornos C etal. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: A clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 2005; 18: 903-11.
18. Nomura K, Aizawa S. Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: A clinicopathologic analysis of 40 cases. Cancer 2000; 89: 1541-6.
19. Strausberg RL, Feingold EA, Grouse LH etal. Generation and initial analysis of more than 15, 000 full-length human and mouse CDNA sequences. Proc Natl Acad Sci USA 2002; 99: 16899-903.